Days after participating in covid-19 vaccine trial, man dies in Bhopal
Premium
2 min read
Share Via
Read Full Story A 42-year-old volunteer from Bhopal in Madhya Pradesh died nearly ten days after he participated in the clinical trial for Covaxin held at a private hospital
Dr Rajesh Kapur, Vice Chancellor, People s Medical College and Hospital where the trial was conducted, told PTI that Deepak Marawi had participated in the Covaxin trial held on December 12, 2020.
TRENDING STORIESSee All
Premium
5 min read
Premium
2 min read
Premium
PPF vs NPS calculator: Key things to know if you want to invest ₹8,000 per month
2 min read
Updated Jan 08, 2021 | 15:11 IST
Bharat Biotech has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year. Representational image | Photo Credit: PTI
New Delhi: The Bharat Biotech International Limited sent an application to the Drugs Controller General of India (DCGI) for conducting the phase 1 trials of an intranasal vaccine against the Covid-19 vaccine, a government official said on Friday.
The matter is yet to be taken up, the government official added. The company has said Phase-1 clinical trials of its new intranasal antidote for the killer virus will begin during February-March this year.
Adar Poonawala
India is all set to receive the 1st Covid-19 vaccine as the Drug Controller General of India (DCGI) on Sunday has approved Oxford AstraZeneca’s CoviShield and Bharat Biotech’s Covaxin for restricted use in India. India is gearing up to begin the biggest vaccination drive for one nation in history. However, controversy has arisen over the name of the Pune-based Serum Institue of India’s vaccine. A civil court in Pune issued a notice to SII on the application of a pharmaceutical company and vendor.
This vaccine, prepared by Oxford University, has been named ‘Covishield’ but at the same time, Adar Poonawala’s company has received notice regarding the name of the vaccine. The notice requested the Serum Institute of India to stop using ‘Covishield’ trademarks or other similar names in its upcoming covid-19 vaccination. This has been filed by Maharashtra’s Nanded-based firm, Cutis-Biotech claiming that they had been using the ‘Kovishield’ trademark s
The SEC made its recommendations in respect of the accelerated approval process request of the SII, Bharat Biotech International Ltd as well as about phase-III trials of Cadila Healthcare Ltd.
New Delhi [India], January 3 (ANI): The Drugs Controller General of India will brief the media at 11 am today at the National Media Centre regarding the coronavirus vaccine.